ITI-5000 / HLB Bio Group - LARVOL DELTA

A UNITE®-based self-amplifying RNA vaccine advances anti-tumor immunity in a murine triple-negative breast cancer model (SITC 2024) - "In this study, we developed an innovative saRNA vaccine (ITI-5000) encoding the tumor-associated antigens HERV-K and CT-83 to promote a balanced T cell response and hinder tumor progression...Ethics Approval This study was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Immunomic Therapeutics, Inc. (ITI)."

Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD4 • CD8 • IFNG • TNFA

Immunomic Therapeutics Announces Presentation on Self-amplifying RNA vaccines using the UNITE platform for Triple-negative Breast Cancer at SITC 39th Annual Meeting 2024 (Businesswire) - "Immunomic Therapeutics...announced today that it will present at SITC 39th Annual Meeting 2024 at the George R. Brown Convention Center in Houston, TX on November 8-10, 2024. Associate Director, Vaccine Discovery, Wei Shen, Ph.D., will present a poster entitled, 'A UNITE-based self-amplifying RNA vaccine advances anti-tumor immunity in a murine triple-negative breast cancer model' on Friday, November 8th & Saturday, November 9th, 2024."

Preclinical • Breast Cancer • Oncology • Solid Tumor